Proton or photon radiation with immunotherapy before surgery for oral cavity cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two types of radiation therapy combined with an immunotherapy drug called pembrolizumab before surgery for oral cavity cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of oral cavity cancer that is not linked to HPV.
- Your cancer is either locally advanced (stage T3 or T4) and has not spread, or it has come back in the same area and you have not had radiation to the head or neck before.
- You are 18 years or older.
- You are able to take care of yourself (ECOG performance status 2 or better).
- Your tumor has a PD-L1 score of at least 1, which means it may respond to immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
This trial tests a combination of two drugs (zanzalintinib and pembrolizumab) given before surgery for HPV-negative oral cavity cancer. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
This study tests whether giving an immunotherapy drug called pembrolizumab before surgery can help treat oral cavity cancer. The researchers will look for biomarkers (clues in your tumor) that may predict how well the treatment works.
This trial tests combining radiation therapy with immunotherapy and chemotherapy before surgery for advanced oral or throat cancer. The goal is to see if this approach can shrink the tumor and improve treatment outcomes.
This trial compares two different treatments after surgery for advanced head and neck cancer (oral or oropharyngeal). It tests whether radiation therapy or continuing an immunotherapy drug (called PD-1 inhibitor) leads to better survival. This study might help you decide which follow-up treatment could be better for your situation.
Hear when a new Locally Recurrent Oral Cavity Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.